Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

HUTCHMED (China) Limited (NASDAQ:HCM) on Tuesday shared data from the Phase 3 registration part of the ESLIM-02 clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA).wAIHA is a condition where the immune system mistakenly makes IgG antibodies that attack and destroy red blood cells at normal body temperature, leading to anemia, fatigue, paleness, and shortness of breath.The trial conducted in China met its primary endpoint of durable hemoglobin (Hb) response ...